Study guide
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells
Scientist in Blood Banking, BB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB
2 Donors and Collection
2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations
3 Processing, Storage, and Component QC
3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control
4 Blood Components
4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors
5 Blood Group Genetics and Transfusion Role
5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence
6 ABO and Lewis Systems
6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System
7 Rh System
7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance
8 Kell, Duffy, Kidd, and MNS
8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System
9 Additional Systems and Antigens
9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens
10 Immunology Foundations
10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties
11 Physiology, Hemostasis, Cytopenias, and Transplantation
11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation
12 Hemolytic Disease of the Fetus and Newborn
12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention
13 Routine Serologic Testing
13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing
14 Antibody Identification
14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps
15 Reagents and Special Techniques
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods
16 Serologic QA and Special Reagents
16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence
17 Indications and Component Therapy
17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy
18 Adverse Effects of Transfusion
18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases
19 Apheresis, Administration, and Patient Blood Management
19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management
20 Laboratory Operations
20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells
Key Takeaways Explain This Topic AI
Monoclonal reagents are single-clone and lot-consistent; blends cover epitopes one clone would miss. Polyclonal reagents see multiple epitopes but vary by lot.
Modern anti-D is usually a low-protein monoclonal IgM plus IgG blend. High-protein Rh reagents require an Rh control; a reactive control invalidates the D type.
AHG is anti-IgG, polyspecific (anti-IgG plus anti-C3b/C3d), or anti-C3b/C3d. Check cells go only into negative AHG tubes and must agglutinate or the test is invalid.
Reagent red cells are group O screening and panel cells, A1 and B reverse cells, A2 cells for anti-A1, and cord cells (I-negative, i-strong).
Control ABO, Rh, and AHG reagents each day of use. Store liquid grouping sera, AHG, and reagent red cells at 1–6 °C. Expiration and hemolysis are hard stops.
Last updated: August 2026
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells
Quick Answer: Monoclonal reagents are single-clone, highly specific, and lot-consistent; polyclonal reagents recognize multiple epitopes. Modern anti-D is usually a monoclonal blend (IgM for immediate-spin D plus IgG for weak D). Anti-A and anti-B are typically monoclonal; anti-A,B catches some weak subgroups and confirms group O. AHG is anti-IgG , polyspecific (anti-IgG + anti-C3b/C3d) , or anti-C3b/C3d . Check cells go into negative AHG tubes and must agglutinate or the test is invalid. Reagent red cells include screening cells, panel cells, A1 and B reverse cells, and cord cells . QC ABO/Rh/AHG each day of use. Store liquid reagents at 1–6 °C . Do not use them after expiration . High-protein Rh reagents require an Rh control ; a reactive control invalidates the D type.
The June 9, 2026 BB outline parks reagents at IV.B . Routine grouping lives in Chapter 13. This section is the bottle on the rack: what is in it, what it can lie about, and how you prove it still works this morning.
Monoclonal versus polyclonal
A polyclonal reagent is a harvest of many B-cell clones, historically from an immunized human or animal. It sees multiple epitopes on the same antigen. That breadth helps when the antigen is heterogeneous (some D variants, some A subgroups), but the product varies by lot, can carry unwanted specificities, and is harder to standardize.
A monoclonal reagent is the product of a single hybridoma or recombinant clone . Specificity is narrow and reproducible. The failure mode is the opposite of polyclonal: a monoclonal anti-D aimed at one epitope can miss a partial D that lacks that epitope. Manufacturers therefore sell blends — two or more monoclonal antibodies in one dropper — so one clone’s blind spot is another clone’s epitope.
On the exam, the usable sentence is: monoclonal = more specific and more consistent; a blend is how the manufacturer covers partial-D and weak-A holes without going back to crude polyclonal serum.
ABO grouping sera
Anti-A and anti-B in current practice are almost always monoclonal IgM . They directly agglutinate at immediate spin. They are formulated as low-protein reagents (protein similar to normal serum, roughly 6% ), so they do not spontaneously agglutinate IgG-coated cells the way a high-protein Rh reagent can.
Anti-A,B is not a lazy mixture you use instead of thinking. It is a reagent that:
Confirms group O (O cells are nonreactive with anti-A, anti-B, and anti-A,B).
Detects some weak A or B subgroups (especially Ax ) that anti-A may miss.
Forward typing uses patient cells plus these sera . Reverse typing does not use grouping sera; it uses A1 and B reagent red cells plus patient plasma. Do not swap those sentences.
Rh reagents: blend anti-D, protein, and the control that saves you
Two historically different anti-D products still appear on BB items.
- Feature Low-protein monoclonal anti-D High-protein (slide / rapid-tube) anti-D
- Typical source Monoclonal IgM , or IgM + IgG blend Human polyclonal in a high-protein diluent (~ 20–24% )
- Routine D type Immediate-spin direct agglutination Direct agglutination, including slide
- Weak D The IgG clone is read at AHG Follow the insert; many labs moved weak D to a low-protein IgG method
False-positive risk Low unless the cell is already agglutinating in every reagent High with DAT-positive or protein-sensitive cells
Required control Manufacturer diluent or 6% albumin when cells are DAT+ or all reagents react Always — the same diluent without anti-D
A blend anti-D typically pairs an IgM monoclonal that agglutinates most D-positive cells at immediate spin with an IgG monoclonal that finishes weak D at AHG. Some blends add a second IgM clone so a partial D that lacks one epitope still types D-positive as a donor. Patient versus donor interpretation of partial D is Chapter 7; the reagent point here is why the bottle says “blend.”
If the Rh control is positive, you do not have a D type. The cells are sticky — coating IgG, rouleaux, a potent cold, or the high-protein diluent itself. Wash, switch to a low-protein monoclonal, or reflex to genotyping. Never subtract a 1+ control from a 3+ anti-D and call the patient D-positive.
Low-protein anti-D does not get you out of a control when every grouping reagent agglutinates the cells or the DAT is already positive. Those are the stems where the manufacturer diluent, 6% albumin, or an inert control cell is still mandatory.
AHG: anti-IgG, polyspecific, anti-C3
Anti-human globulin bridges IgG or C3 already on red cells so you can see it. Chapter 10 gave the immunology. This chapter is the bottle and the QC.
- Reagent Detects Everyday use
- Monospecific anti-IgG Bound IgG Most gel/column IAT cards; split a positive DAT
- Polyspecific AHG IgG + C3b/C3d Tube DAT; some tube IAT methods
- Monospecific anti-C3b/C3d Bound complement Split a positive DAT; cold AIHA / some drugs
A gel card labeled anti-IgG will not detect a complement-only coating. That is not a reagent failure; it is the wrong reagent for that question. A DAT workup that stops at “polyspecific positive” is incomplete — split it with anti-IgG and anti-C3.
AHG is neutralized by leftover serum globulin . That is why tube IAT/DAT washing exists, and why check cells exist.
Check cells
Check cells (Coombs control cells) are group O red cells coated with IgG . After you read an AHG test as negative , you add check cells and recentrifuge.
Agglutination → AHG was present and active, and washing was adequate. The original negative result stands.
No agglutination → the test is invalid . You may have forgotten AHG, used inactive AHG, or left unbound IgG in the tube so AHG was neutralized before it could find the test cells.
Check cells go into negative AHG tubes. They do not confirm a positive AHG result — those cells are already agglutinated. They also do not prove the original antibody was IgG versus complement; they only audit the AHG reagent and the wash .
Reagent red cells
Antibody-detection cells are group O so anti-A and anti-B in the patient do not agglutinate the panel.
Product What it is Why you own it
Screening cells 2 or 3 group O cells with a complementary antigen profile Antibody screen. Homozygous expression of dosage antigens (Jka, Fya, and friends) is the point.
Panel cells 10–16 group O cells plus an antigen matrix Antibody identification and rule-out.
A1 reverse cells A1 adult cells Reverse ABO. Also the cell that reacts with anti-A1 .
B reverse cells B adult cells Reverse ABO.
A2 cells A2 adult cells Prove anti-A1 (reactive with A1, nonreactive with A2).
Cord cells Group O (or A/B) cord red cells I-negative / i-strong . Separate anti-I from anti-i; sometimes ABO HDFN workups.
Screening and panel cells expire on a short clock and hemolyze or lose antigen strength as they age. A visually hemolyzed vial is out of service even if the printed date has not arrived. Cord cells are not extra screening cells. They are an I/i reagent .
Daily QC, storage, expiration
Each day of use , control:
ABO sera against known A, B, and O cells (the positive and negative reactions the SOP names).
Anti-D against known D-positive and D-negative cells.
AHG with IgG-coated cells (and a negative control as required). In many tube systems the check-cell lot plus a documented negative control satisfies the AHG check.
Visual inspection is QC: turbidity, precipitate, hemolysis, a black reagent-cell supernatant, a frozen bottle that was supposed to stay liquid.
Storage for liquid grouping sera, AHG, and reagent red cells is 1–6 °C. Do not freeze reagent red cells. Do not leave the rack on the bench for the whole shift and call that refrigerated. Expiration is a hard stop. An in-date hemolyzed screening cell is also a hard stop. Manufacturer inserts win when they are tighter than the generic 1–6 °C sentence.
- Exam traps
- Reading a positive Rh control as “the patient is just strongly D-positive.”
Using check cells on a positive AHG tube and thinking that validates the specificity.
Storing AHG at room temperature “because it is used all day.”
Treating cord cells as ordinary screening cells.
Calling anti-A,B optional decoration rather than the reagent that finds some Ax cells and confirms O.
Assuming every anti-D is high-protein. Most current bottles are low-protein monoclonal blends .